2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

2316 An engineered lytic bacteriophage selectively targeting enterococcus faecalis ameliorates murine intestinal acute graft-versus-host disease by disrupting the Macrophage–Epithelial IFN-γ axis

Xue Dong, Xi Zhang, MD2
1 Xinqiao Hospital of Army Medical University, Chongqing, China
2 Xinqiao Hospital of Army Medical University, Chongqing, China

Introduction: Gut colonization by Enterococcus faecalis (E.f.) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with higher mortality from acute graft-versus-host disease (aGVHD). We found that E.f. worsens intestinal aGVHD through two mechanisms: it upregulates epithelial MHC-II antigen presentation in an IFN-γ–dependent manner, and it drives TLR2/PAFR-mediated M1 macrophage polarization that produces CXCL10, CCL2, and CCL3 to recruit Th1 and CD8? effector T cells. Antibiotics lower the E.f. burden but also deplete protective commensals and select for resistance. A strategy that clears E.f. selectively while sparing the commensal microbiota and dampening local immune activation is therefore needed.
Methods: We engineered an artificial lytic bacteriophage (ALB) by conjugating an E.f.-specific display-peptide phage (clone A12, from phage-display biopanning) to a silver-doped Prussian blue catalytic antioxidant (SPB) with SOD- and catalase-like ROS-scavenging activity. ALB was encapsulated in FDA-approved inulin gel (InuGel) to give ALBGel, an oral, colon-targeted formulation. Efficacy was tested in vitro and in an E.f.-aggravated allo-BMT model (C57BL/6→BALB/c).
Results: A12 bound E.f. specifically and did not bind wild-type M13 or control bacteria. ALB almost completely suppressed E.f. growth and cleared its biofilm. Because the phage focused killing onto E.f., ALB spared probiotics (Bifidobacterium, L. rhamnosus, L. plantarum), and its antioxidant activity further shielded them from ROS. InuGel protected ALB in gastric acid and released it in the colon upon exposure to bacterial enzymes, extending intestinal retention to 24 h. At the cellular level, ALB repolarized macrophages from M1 to M2, suppressed ROS and NF-κB signaling, and lowered TNF-α, IL-6, IL-1β, CXCL10, CCL2, and CCL3 while raising IL-10 and TGF-β. It also restored the tight-junction proteins ZO-1 and Claudin, reduced epithelial permeability, and interrupted the oxidative-stress cascade linking ROS to lipid peroxidation and DNA damage. In vivo, ALBGel lowered clinical scores and weight loss and extended median survival from 16 to 30 days, a 50% improvement over untreated aGVHD; every single component was far less effective. Treatment shifted intestinal macrophages toward M2, downregulated the IFN-γ/MHC-II axis, decreased Th1 and Th17 cells while expanding Treg in mesenteric lymph nodes, and reduced systemic inflammatory cytokines. ALBGel rebuilt the mechanical (ZO-1), mucus (goblet cells, MUC2), and chemical (Paneth-cell lysozyme) barriers, promoted crypt regeneration (Ki67), and relieved oxidative stress with lower MDA and γ-H2AX. 16S rRNA sequencing confirmed that ALBGel remodeled the gut community: ANOSIM showed clear separation between untreated and treated mice (r=0.893, p=0.001), α-diversity (Chao1 and Shannon) recovered after treatment, and the Enterococcus- and Escherichia–Shigella-dominated dysbiosis gave way to a Lactobacillus-, Bacteroides-, and Akkermansia-enriched community. By LEfSe, SCFA-producing, barrier-protective taxa were enriched after treatment, including Blautia, Akkermansia, Bifidobacterium, Lachnospiraceae_NK4A136_group, and Butyricimonas, consistent with selective removal of E.f. and recovery of the symbiotic microbiota.
Conclusions: ALBGel is a species-selective platform coupling precise E.f. clearance with catalyst-mediated antioxidation and prebiotic colon-targeted delivery. By simultaneously disrupting the macrophage-amplification and epithelial antigen-presentation arms that converge on the IFN-γ axis, while restoring the intestinal barrier and preserving commensal bacteria, ALBGel offers a promising microbiota-sparing therapy for intestinal aGVHD after allo-HSCT.

Xue Dong: No relevant conflicts of interest to declare.